A novel adenylyl cyclase type 5 inhibitor that reduces myocardial infarct size even when administered after coronary artery reperfusion.
- DOI
- 10.1016/j.yjmcc.2018.05.014
- Published
- 2018 Aug
- Container
- Journal of molecular and cellular cardiology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.yjmcc.2018.05.014,
title = {A novel adenylyl cyclase type 5 inhibitor that reduces myocardial infarct size even when administered after coronary artery reperfusion.},
author = {Zhang J and Levy D and Oydanich M and Bravo CA and Yoon S and Vatner DE and Vatner SF},
year = {2018},
journal = {Journal of molecular and cellular cardiology},
doi = {10.1016/j.yjmcc.2018.05.014},
url = {https://doi.org/10.1016/j.yjmcc.2018.05.014}
}RIS
TY - JOUR TI - A novel adenylyl cyclase type 5 inhibitor that reduces myocardial infarct size even when administered after coronary artery reperfusion. AU - Zhang J AU - Levy D AU - Oydanich M AU - Bravo CA AU - Yoon S AU - Vatner DE AU - Vatner SF PY - 2018 JO - Journal of molecular and cellular cardiology DO - 10.1016/j.yjmcc.2018.05.014 UR - https://doi.org/10.1016/j.yjmcc.2018.05.014 ER -
APA
J, Z., D, L., M, O., CA, B., S, Y., DE, V., & SF, V. (2018). A novel adenylyl cyclase type 5 inhibitor that reduces myocardial infarct size even when administered after coronary artery reperfusion.. Journal of molecular and cellular cardiology. https://doi.org/10.1016/j.yjmcc.2018.05.014
Source records
- pubmed · retrieved 2026-09-27T14:15:14.114Z